Initial Observations of Intravenous CD-NP, Chimeric Natriuretic Peptide, on Renal Functions in Chronic Heart Failure Patients
2009; Elsevier BV; Volume: 15; Issue: 6 Linguagem: Inglês
10.1016/j.cardfail.2009.06.180
ISSN1532-8414
AutoresHsiao D. Lieu, Steven R. Goldsmith, Joel Neutal, Barry M. Massie, J. C. Burnett,
Tópico(s)Heart Failure Treatment and Management
ResumoBackground: Nesiritide, a natriuretic peptide with arterial vasodilator property, has been associated with worsening of renal function. CD-NP is a novel chimeric natriuretic peptide engineered with venodilatory and renal protective properties. The effects of CD-NP in patients (pts) with chronic heart failure (HF) are unknown. Accordingly, the purpose of this study was to evaluate the effects of increasing doses of CD-NP on diuresis in HF pts. Methods: Chronic HF pts with systolic blood pressure ≥ 110 mmHg and EF < 40 % with signs and symptoms of HF (NYHA class 2/3) received escalating doses of CD-NP infusion for 24 hours in this open-label trial.
Referência(s)